CILA’s proprietary, gene-agnostic platform, CIL-Key™, is designed to enable the development of breakthrough inhaled RNA therapeutics and vaccines for pulmonary diseases — potentially unlocking new ...
Under the two-year project timeline, researchers will spend the first year optimizing vaccine candidates and evaluating their ...
The approval of messenger RNA (mRNA) based COVID-19 vaccines marked a pivotal scientific milestone, establishing mRNA as an innovative drug modality with immense therapeutic potential. However, due to ...
Next-generation cell therapies are reshaping therapeutics by precisely engineering living cells for both ex vivo and in vivo applications. Cutting-edge tools—including Cas enzymes (Cas9, Cas12a), base ...
RNA-based hTERT therapy may enhance telomere activity, improving lung cell health in pulmonary fibrosis (PF). Telomere dysfunction is a significant risk factor for PF, with telomerase reactivation ...
Authorization expands academic and industry researcher access for LNP delivery optimization, mRNA vaccine development and gene therapy research A new agreement between Promega Corporation and the RNA ...
MADISON, Wis.--(BUSINESS WIRE)--A new agreement between Promega Corporation and the RNA & Formulation Core at the University of British Columbia will enable the facility to manufacture and distribute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results